Acrivon Therapeutics, Inc. Common Stock (ACRV)

A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.

Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also fell, dropping, 0.39% to 5,182.36. Check This Out: Robinhood To Rally Around 51%? Here Are 10 Top Analyst Forecasts For Tuesday   Leading and Lagging Sectors   Real estate shares jumped by 0.8% on Tuesday. In trading on Tuesday, financial shares fell by 0.7%.   Top Headline   The NFIB Small Business Optimism Index declined for a third straight month to a reading of 88.5 in March, compared to market estimates of 90.2.   Equities Trading UP   Laser Photonics Corporation (NASDAQ: LASE) shares shot up 98% to $2.8450 after the company announced it secured an order for its LaserTower COMPACT marking and engraving system from L3Harris Technologies. Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV) got a boost, surging 95% to $11.54. The company announced a $130 million private placement financing. Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) shares ...

A more selective small-cap index has consistently outperformed the Russell 2000

These two healthcare stocks have crushed the broader markets this year.